Intralytix, Inc. is a biotechnology company focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.

Bacteriophages (bacteria-eater: from the Greek phago meaning "to eat" or "to develop at the expense of") are the most abundant microorganisms on earth. They are the natural enemies of bacteria. Lytic bacteriophages can very effectively kill their targeted specific bacteria without affecting anything else, ensuring an unprecedented level of safety for an antimicrobial.

In The News

Intralytix, Inc. and Ferring Pharmaceuticals partner to develop bacteriophage treatments

Ferring Pharmaceuticals is partnering with Intralytix, Inc to develop and commercialise bacteriophage-based treatments for conditions associated with the presence of pathogenic bacteria or dysbiosis of the microbiome.

Intralytix Receives USDA, NIFA Phase II SBIR Grant To Develop A Phage-Based Application To Protect Hatchery-Raised Oysters From The Bacterial Pathogens Vibrio tubiashii and Vibrio coralliilyticus

Intralytix, Inc., announced today that the company has received a SBIR Phase II grant from the U.S. Department of Agriculture (USDA), National Institute of Food and Agriculture (NIFA)

Intralytix and Ferring Pharmaceuticals Collaborate In Novel Bacteriophage-Based IBD Drug Development Project

Intralytix, Inc., announced today that it has entered into a collaboration agreement with Ferring Pharmaceuticals, a research-driven, specialty biopharmaceutical group headquartered in St. Prex, Switzerland.

See more...



Technology

Food Safety

Environmental Sanitation

Veterinary Applications

Human Therapeutics

Probiotics